Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
In order to determine the prevalence and molecular characterization of hemoglobinopathies in the Wuxi region of Jiangsu Province in the People's Republic of China (PRC), a total of 10,297 healthy people selected from a regional hospital were screened. Hemoglobin (Hb) electrophoresis, complete blood cell (CBC) count, polymerase chain reaction (PCR), DNA sequencing, reverse dot-blot and multiplex ligation-dependent probe amplification (MLPA) were used to detect Hb variants, thalassemias and hereditary persistence of fetal Hb (HPFH). Two thousand and twenty-one adult subjects were screened for thalassemia, five cases were identified as α-thalassemia (α-thal) carriers including three cases of the -α(3.7) (rightward) deletion, one case of the - -(SEA) deletion and one case of β-thal [IVS-II-654 (C>T), (HBB: c.316-197C>T)]. The incidence of Hb variants, thalassemia and HPFH/δβ-thal were 0.136% (14/10,297), 0.25% (5/2021) and 0.0001% (1/10,297), respectively. Eight genotypes of Hb variants were found, including Hb E [β26(B8)Glu→Lys, GAG>AAG; HBB: c.79G>A], Hb J-Bangkok [β56(D7)Gly→Asp (GGC>GAC); HBB; c.170G>A], Hb G-Coushatta [β22(4)Glu→Ala (GAA>GCA); HBB: c.68A>C], Hb Queens [α34(B15)Leu→Arg (CTG>CGG) (α2 or α1); HBA2: c.104T>G (or HBA1)], Hb I [α16(A14)Lys→Glu, AAG>GAG (α1); HBA1: c.49A>G], Hb Beijing [α16(A14)Lys→Asn (AAG>AAC or AAT) (α2 or α1); HBA2: c.51G>C (or HBA1) or 51G>T (or HBA1)], Hb Ube-2 [α68(E17)Asn→Asp (AAC>GAC) (α2 or α1); HBA2: c.205A>G (or HBA1)] and Hb G-Taipei [β22(B4)Glu→Gly (GAA>GGA); HBB: c.68A>G]. A Sicilian δβ(0)-thal, identified for the first time in Asia, was also found in this survey.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.3109/03630269.2013.807285 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multi-Parametric MRI for Early Detection of Renal Fibrosis and Evaluation of Therapeutic Effect of Asiatic Acid in an Experimental Rat.
NMR Biomed
October 2025
Department of Radiology, Tianjin First Central Hospital, Nankai University, Tianjin Institute of Imaging Medicine, Tianjin, China.
Objectives: Early diagnosis and timely treatment of renal fibrosis can improve the prognosis of patients with nephropathy. We aim to investigate the utility of multi-parametric MRI for evaluating early renal fibrosis and therapeutic efficacy in a rat model.
Methods: Eighty-four male SD rats receiving tail vein injection of adriamycin doxorubicin (ADR) to establish renal fibrosis models were utilized.
Alternative zinc binding peptides as potential tags for recombinant protein purification.
J Inorg Biochem
October 2025
Department of Chemistry, East Texas A&M University, 2600 S Neal Street, Commerce, TX 75428, USA. Electronic address:
Efficient binding of peptides and proteins to metal-chelating resins is a cornerstone of modern biochemical purification. This study evaluates a novel heptapeptide sequence, acetyl-Aa-Aa-Gly-Pro-Aa-His-Cys, where Aa = His or Asp, Aa = Cys or Asp and Aa = Tyr or Gly for its capacity to bind zinc-chelating resin consisting of divalent zinc chelated by iminodiacetate coupled to 6 % cross-linked agarose beads. Comparisons were made against the widely utilized 7 × His tag using an internal standard method with ion mobility - mass spectrometry analyses and ultra-violet absorption analyses, which quantified the binding efficiency and selectivity of these peptides under pH 8 conditions and the elution from the zinc resin using pH 3.
View Article and Find Full Text PDFUnravelling the enzymatic wood decay repertoire of Cerrena zonata: A multi-omics approach.
Microbiol Res
September 2025
Justus Liebig University Giessen, Institute of Food Chemistry and Food Biotechnology, Heinrich-Buff-Ring 17, Giessen 35392, Germany. Electronic address:
Lignocellulosic biomass (LCB), such as wheat straw, bagasse, or wood, is a cost-effective, sustainable carbon source but remains challenging to utilize due to the recalcitrance of lignin, which hinders efficient carbohydrate hydrolysis. Effective LCB degradation demands a wide range of enzymes, and commercial enzyme cocktails often require physical or chemical pretreatments. A fully enzymatic degradation could drastically improve the efficiency of these processes.
View Article and Find Full Text PDFSafety of Baricitinib in Adults with Severe Alopecia Areata from Two Phase III Trials Over a Median of 2.3 Years and Up to 4 Years of Treatment.
Am J Clin Dermatol
July 2025
University of Melbourne, Melbourne, VIC, Australia.
Background: We report pooled safety data for baricitinib treatment of severe alopecia areata in patients in BRAVE-AA1 (phase II/III) and BRAVE-AA2 (phase III), including data from the long-term extension and bridging extension periods.
Methods: Data are reported from the extended dataset (patients receiving continuous baricitinib 2 mg or 4 mg) and the all-baricitinib dataset (all patients receiving any dose of baricitinib at any time during the trials). Safety outcomes include treatment-emergent adverse events, adverse events of special interest, and abnormal changes in laboratory test results.
Understanding eyebrow and eyelash involvement in patients with alopecia areata and responsiveness to treatment with baricitinib.
Br J Dermatol
July 2025
Eli Lilly and Company, Indianapolis, IN, USA.
Background: Eyebrow and eyelash (EB/EL) involvement is an important consideration in the assessment of alopecia areata (AA) severity.
Objectives: To report on the integrated results from BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259), characterizing EB/EL involvement at baseline in patients with AA and response to baricitinib treatment.
Methods: BRAVE-AA1 (NCT03570749) and BRAVE-AA2 (NCT03899259) were randomized double-blind placebo-controlled trials conducted at 169 centres in 10 countries.